Ventyx Biosciences (VTYX)
(Delayed Data from NSDQ)
$2.58 USD
-0.14 (-5.15%)
Updated Aug 5, 2025 04:00 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VTYX 2.58 -0.14(-5.15%)
Will VTYX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VTYX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTYX
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
VTYX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VTYX
Commit To Buy Ventyx Biosciences At $2.50, Earn 56.9% Annualized Using Options
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)
Oppenheimer Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)
Hold Rating for Ventyx Biosciences Amid Promising Early Data and Strategic Uncertainties
Positive Outlook on Ventyx Biosciences Due to Promising Developments in Neuro-Inflammatory Treatments